Multiple Myeloma (Event Driven)

Transcription

1 Brochure More information from Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite being a relatively small oncology indication in terms of incidence. Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents drive market expansion, but untapped market potential remains for agents that can improve survival and reduce peripheral neuropathy and/or myelosuppression compared with currently available agents. Contents: Executive Summary What are the key parameters of the multiple myeloma market? What factors are driving the market for multiple myeloma therapies? What factors are constraining the market for multiple myeloma therapies? What are the drug development activities of note in multiple myeloma? What do the experts say? What key challenges and opportunities remain? 1 Etiology and Pathophysiology Disease Pathophysiology Normal Plasma Cells Monoclonal Gammopathies Monoclonal Gammopathy of Undetermined Significance Asymptomatic Myeloma Symptomatic Multiple Myeloma Solitary Bone and Extramedullary Plasmacytomas Cytogenetic Changes Early Events Late Events Epigenetic Changes Genetic Testing Bone Marrow Microenvironment Myeloma Stem Cells Risk Factors Staging and Prognostic Factors Pathways and Drug Targets Potential Therapeutic Targets for Myeloma Treatment Cell-Surface Molecules Disruption of Aberrant Signaling Pathways Angiogenesis Bone Metabolism Other Cellular Processes 2 Epidemiology and Patient Populations Disease Definition Methods Newly Diagnosed Cases of Multiple Myeloma Subpopulations Stage at Diagnosis Diagnosed and Drug-Treated Populations Percentage Diagnosed Drug-Treatable and Drug-Treated Populations First Line Second Line Third Line

2 3 Current Therapy and Medical Practice Diagnosis Treatment Guidelines Clinical Trial End Points Drug Treatment Myeloma Treatment Treatment of Bone Complications Commonly Prescribed Drugs Regimen Dosing Clinical Analysis of Therapies Used for Asymptomatic Multiple Myeloma Clinical Analysis of Therapies Used for First-Line, Transplant-Eligible Multiple Myeloma Clinical Analysis of Therapies Used for First-Line Maintenance, Consolidation, and Tandem-Transplantation Treatments After Initial ASCT Clinical Analysis of Therapies Used for First-Line Transplant-Ineligible Multiple Myeloma Clinical Analysis of Therapies Used for Relapsed/Refractory Multiple Myeloma Clinical Development General Treatment Algorithm Country-Specific Treatment Practices Reimbursement 4 Unmet Needs Effective Therapies That Lead to Cure/Long-Term Remission Therapies for Refractory Patients Therapies That Target Myeloma Cells Tailoring of Novel Therapies Well-Tolerated Therapies Preventive Therapies for Patients with MGUS or Asymptomatic Myeloma 5 Emerging Therapies Future Positioning of Key Competitors Early-Stage Therapies Drug Development and Regulatory Hurdles Proteasome Inhibitors Carfilzomib Immunotherapies Pomalidomide Pegylated Interferon Elotuzumab MAGE-A3/NY-ESO-1 Vaccine Therapy 160 mtor/akt/interleukin-6 Inhibitors Perifosine Enzastaurin Siltuximab Temsirolimus Histone Deacetylase Inhibitors Panobinostat Vorinostat Romidepsin Cytotoxic Chemotherapy

3 Bendamustine Kinase Inhibitors Masitinib Angiogenesis Inhibitors Bevacizumab Sorafenib Heat-Shock-Protein Inhibitors Tanespimycin Apoptosis Stimulators Plitidepsin 6 Market Outlook Segment-Specific Trends First-Line Multiple Myeloma Immunomodulatory Agents Proteasome Inhibitors Cytotoxic Chemotherapy Relapsed/Refractory Multiple Myeloma Immunomodulatory Agents Proteasome Inhibitors Cytotoxic Chemotherapy Histone Deacetylase Inhibitors Akt Inhibitors Alternative Market Scenario Appendix A Bibliography Multiple Myeloma Appendix B Market Forecast Methodology Bottom-Up Market Forecasting Patient Populations Drug-Specific Assumptions General Sources of Data Pricing, Dosing, Days of Therapy, and Compliance Assumptions General Statements about Pricing Dosing, Cycles and Compliance Generics Erosion Emerging Therapy Prices Appendix C Experts Interviewed Multiple Myeloma Tables and Figures Table 1-1 Conditions Related to Multiple Myeloma Table 1-2 Molecular Biology of Multiple Myeloma Table 1-3 Durie-Salmon Staging of Multiple Myeloma Table 1-4 International Staging System for Multiple Myeloma Table 1-5 Novel Prognostic and Diagnostic Biomarkers Table 2-1 Number of Diagnosed Incident Cases of Multiple Myeloma in the Major Pharmaceutical Markets, by Stage at Diagnosis,

4 Table 2-2 Key Sources for Multiple Myeloma Epidemiology Table 3-1 Treatment Providers and Diagnostic Patterns in the Major Markets for Multiple Myeloma Table 3-2 Expert Insight on Diagnosis of Multiple Myeloma Table 3-3 Multiple Myeloma Treatment Guidelines by Market Table 3-4 Key End Points Used in Clinical Trials for Multiple Myeloma Table 3-5 Expert Insight on End Points for Multiple Myeloma Table 3-6 Brand and Manufacturer of Current Therapies to Treat Multiple Myeloma Table 3-7 Current Drug Classes Used for Multiple Myeloma Table 3-8 Current Regimen Dosing for Multiple Myeloma Table 3-9 Efficacy Achievements of First-Line Multiple Myeloma Treatment Table 3-10 Most Frequent Toxicities Encountered During First-Line Induction Therapy Table 3-11 Efficacy Achievements in the Relapsed/Refractory Setting for Multiple Myeloma Table 3-12 Most Frequent Toxicities Encountered During Relapsed/Refractory Treatment Table 3-13 Select Phase III Trials Investigating New Combinations of Bortezomib, Thalidomide, and Lenalidomide in the Treatment of Multiple Myeloma Table 3-14 Select Results from Novel Combination Regimens Emerging into Clinical Practice and Currently in Development Table 3-15 Most Commonly Prescribed Regimens for Multiple Myeloma, by Line Table 3-16 Expert Insight: Therapies Used to Treat First-Line, Transplant-Eligible Multiple Myeloma Patients Table 3-17 Expert Insight: Therapies Used to Treat First-Line, Transplant-Ineligible Multiple Myeloma Patients Table 3-18 Expert Insight: Therapies Used to Treat Relapsed/Refractory Multiple Myeloma Patients Table 3-19 Reimbursement Environment for Multiple Myeloma, by Market Table 5-1 Emerging Therapies in Development for Multiple Myeloma Table 5-2 Estimated Launch Dates for Key Emerging Therapies for the Treatment of Multiple Myeloma Table 5-3 Therapies in Early-Stage Development for Multiple Myeloma Table 6-1 Sales of Drugs to Treat Multiple Myeloma (all populations) in the Major Pharmaceutical Markets, Table 6-2 Timeline of Key Market Events for Multiple Myeloma Table 6-3 Alternative Market Scenario for the Multiple Myeloma Market Through 2020 Table B-1 Sources for Drug Prices Table B-2 Dosing Assumptions Figure 1-1 Clinical Manifestations of Multiple Myeloma Figure 1-2 Plasma Cell and Myeloma Cell Process

5 Figure 1-3 The Bone Marrow Microenvironment Figure 1-4 Pathways Involved in Cytokine-Mediated Tumor Cell Proliferation, Survival, and Migration Figure 1-5 Cell-Surface Molecules on Myeloma Cells and Bone Marrow Stromal Cells Figure 1-6 Mechanism of Bone Destruction in Multiple Myeloma Figure 2-1 Diagnosed Indicence of Multiple Myeloma in the Major Pharmaceutical Markets, Figure 2-2 Multiple Myeloma, Stage at Diagnosis, 2010 Figure 2-3 Diagnosed Incident Cases of Multiple Myeloma, by Gender, 2010 Figure 2-4 Multiple Myeloma Patient Flow Figure 3-1 General Treatment Algorithm for Multiple Myeloma Figure 4-1 Unmet Needs: Attainment and Remaining Opportunity in Multiple Myeloma Figure 6-1 Multiple Myeloma Therapies, : Market Share Figure 6-2 Timeline of Near-Term Events in Multiple Myeloma Figure 6-3 Sales of Leading Therapies in the Multiple Myeloma Market, by Setting, Figure 6-4 Immunomodulatory Drugs' Share of the Multiple Myeloma Market, Figure 6-5 Leading Therapies in the Multiple Myeloma Market, Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

6 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct. Product Name: Web Address: Office Code: Multiple Myeloma (Event Driven) SC Product Format Please select the product format and quantity you require: Electronic (PDF) - Single User: Quantity USD Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

7 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World